CYP2C8

CYP2C8 CYP2C8 is a member of the cytochrome P450 superfamily, specifically the CYP2C subfamily, which plays a crucial role in the metabolism of various drugs and endogenous compounds. It is primarily expressed in the liver and is involved in the oxidation of substrates, leading to their activation or inactivation. The enzyme is also known to interact with various pharmacokinetics and pharmacodynamics pathways. CYP2C8 is located on chromosome 10 in humans.

Function

The primary function of CYP2C8 is to catalyze the oxidation of various substrates, including fatty acids, steroids, and xenobiotics. This process involves the hydroxylation of the substrate, which can lead to its activation or inactivation. CYP2C8 has been shown to interact with various proteins, including cytochrome P450 reductase, to facilitate its catalytic activity. The enzyme has also been implicated in the metabolism of arachidonic acid, leading to the production of vasodilators and vasoconstrictors.

Genetics

CYP2C8 is encoded by the CYP2C8 gene, which is located on chromosome 10q23.33 in humans. The gene has several variants, including CYP2C8*1, CYP2C8*2, and CYP2C8*3, which can affect the enzyme's activity and substrate specificity. These variants have been associated with altered metabolism of various drugs and endogenous compounds. The CYP2C8 gene is also subject to regulation by various transcription factors, including aryl hydrocarbon receptor.

Substrates and inhibitors

CYP2C8 has a wide range of substrates, including paclitaxel, cerivastatin, and aflatoxin B1. The enzyme is also inhibited by various compounds, including ketoconazole, fluconazole, and gemfibrozil. These interactions can affect the metabolism of various drugs and endogenous compounds, leading to changes in their pharmacokinetics and pharmacodynamics.

Clinical significance

CYP2C8 has been implicated in various clinical conditions, including cancer, cardiovascular disease, and metabolic disorders. The enzyme's activity has been shown to affect the metabolism of various drugs, including chemotherapeutic agents and statins. Altered CYP2C8 activity has also been associated with changes in blood pressure and lipid profiles. Pharmacogenomics studies have identified CYP2C8 variants that can predict drug response and adverse reactions.

Pharmacogenomics

The pharmacogenomics of CYP2C8 has been extensively studied, with various variants identified that can affect the enzyme's activity and substrate specificity. These variants have been associated with altered metabolism of various drugs and endogenous compounds, leading to changes in their pharmacokinetics and pharmacodynamics. Genetic testing for CYP2C8 variants can help predict drug response and adverse reactions, allowing for personalized medicine approaches. Pharmacogenomics studies have also identified potential therapeutic targets for various clinical conditions, including cancer and cardiovascular disease. Category:Cytochrome P450 enzymes